Report #2894947

Received Apr 30, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: WA
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RV5	ROTAVIRUS (ROTATEQ)	MERCK & CO. INC.	1	—	OT

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

received their 1st dose of ROTATEQ in 2025 and is now delayed for the second dose; Confirmed no symptomatic adverse events / No additional AE; This spontaneous report was received from a medical assistant and refers to an infant patient of unknown gender. The patient's medical history, past medications and concomitant medications were not reported. On an unknown date in 2025, the patient was vaccinated with the first dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral solution, administered orally (exact dose, lot# and expiry date were not reported), for prophylaxis. At the reporting time, the patient was delayed for the second dose (Inappropriate schedule of product administration). The dose has been delayed because the patient's doctor was on maternity leave and the patient's family was reluctant to go to another clinic to continue rotavirus vaccine, live, oral, pentavalent (ROTATEQ). The patient has been due for the second dose and was looking for guidance. Confirmed no symptomatic adverse events. No additional adverse event was reported.